Literature DB >> 9298740

A DNA polymorphism at the angiotensin II type 1 receptor (AT1R) locus and myocardial infarction.

K E Berge1, A Bakken, M Bøhn, J Erikssen, K Berg.   

Abstract

Two hundred and thirty-five survivors of myocardial infarction (MI) were compared to 384 controls with respect to distribution of genotypes and gene frequencies in the A1166C polymorphism at the angiotensin II type 1 receptor (AT1R) locus. No differences in allele frequencies or genotype distribution were observed when all patients were compared with all controls. When comparing CC homozygotes with the combined group of CA heterozygotes and AA homozygotes (CA/AA), a difference in borderline significance between the MI group and controls was observed (p=0.05). In males alone, this difference was much more pronounced because of the larger proportion of males with the CC genotype in MI cases than in male controls (p=0.01). No significant differences were observed between female cases and controls. No interaction between the insertion/deletion (I/D) polymorphism at the angiotensin I-converting enzyme (ACE) locus and the polymorphism at the AT1R locus was detected. When subdividing the subjects into a "low-risk" and a "high-risk" group, based on levels of apolipoprotein B (apoB) and body mass index (BMI), and whether or not the person used lipid-lowering drugs, the frequency of CC homozygotes in male cases of the "low-risk" group differed significantly compared to the frequency in male controls of the "low-risk" group (p<0.001). No differences were observed in females, but the number of "low-risk" group female cases was low (n=3). Thus, CC homozygosity appears to be associated with MI in Norwegian males, especially among those with a "low-risk" phenotype.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9298740     DOI: 10.1111/j.1399-0004.1997.tb02521.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

Review 1.  Angiotensin I-converting enzyme: genotype and disease associations.

Authors:  D Crisan; J Carr
Journal:  J Mol Diagn       Date:  2000-08       Impact factor: 5.568

Review 2.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

Review 3.  The ACE gene and human performance: 12 years on.

Authors:  Zudin Puthucheary; James R A Skipworth; Jai Rawal; Mike Loosemore; Ken Van Someren; Hugh E Montgomery
Journal:  Sports Med       Date:  2011-06-01       Impact factor: 11.136

4.  Genes of renin angiotensin system and coronary heart disease.

Authors:  T F Ashavaid; K K Shalia; K G Nair; J J Dalal
Journal:  Indian J Clin Biochem       Date:  2000-08

5.  Renin-angiotensin-aldosterone system polymorphisms: a role or a hole in occurrence and long-term prognosis of acute myocardial infarction at young age.

Authors:  Erica Franco; Luigi Palumbo; Francesca Crobu; Matteo Anselmino; Simone Frea; Giuseppe Matullo; Alberto Piazza; Gian Paolo Trevi; Serena Bergerone
Journal:  BMC Med Genet       Date:  2007-05-22       Impact factor: 2.103

6.  Association between angiotensin II type 1 receptor polymorphism and sudden cardiac death in myocardial infarction.

Authors:  Peter Kruzliak; Gabriela Kovacova; Olga Pechanova; Stefan Balogh
Journal:  Dis Markers       Date:  2013-09-12       Impact factor: 3.434

7.  Angiotensin Receptors: Structure, Function, Signaling and Clinical Applications.

Authors:  Khuraijam Dhanachandra Singh; Sadashiva S Karnik
Journal:  J Cell Signal       Date:  2016-04-08

Review 8.  Antibodies against Angiotensin II Type 1 and Endothelin 1 Type A Receptors in Cardiovascular Pathologies.

Authors:  Giovanni Civieri; Laura Iop; Francesco Tona
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.